v3.26.1
REVENUE RECOGNITION (Tables)
12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
SCHEDULE OF DISAGGREGATION OF REVENUE

Revenue disaggregated by product for the years ended December 31, 2025 and 2024 is as follows:

 

Product 

Year Ended

December 31, 2025

  

Year Ended

December 31, 2024

 
ARBLI™ (SCN-102, Losartan Potassium Oral Suspension)  $431,609   $- 
Legacy TrXade product revenues   -    136,643 
Total revenues  $431,609   $136,643